1 recruiting, 1 unknown, 1 withdrawn. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Squamous Cell Carcinoma of the Penis: new trials by email Literature Review of Squamous Cell Carcinoma of the Penis trials Research Report on Squamous Cell Carcinoma of the Penis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... Sacituzumab govitecan, Atezolizumab - Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract | Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2024-08-01 | 2026-10-16 |
| PEN-866 in Patients With Advanced Solid Malignancies PEN-866 Sodium, fluorouracil, Folinic acid - Carcinoma, Endometrial Adenocarcinoma | Phase 1 / Phase 2 | Unknown | Tarveda Therapeutics | 340 | 2017-08-29 | 2022-02-17 |
| Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) Cetuximab, TIP - Squamous Cell Carcinoma of the Penis | Phase 2 | Withdrawn | Centre Leon Berard | 2016-02-01 | 2016-02-25 |
Anus Neoplasms (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Anus Diseases (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Lung Diseases (1)
Cetuximab (1) · Fluorouracil (1) · Leucovorin (1) · atezolizumab (1) · niraparib (1) · sacituzumab govitecan (1)
Centre Leon Berard (1) · National Cancer Institute (NCI) (1) · Tarveda Therapeutics (1)
United States (2) · France (1)
Andrea B Apolo, M.D. (1) · Anish Thomas, MD (1)